A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

• Status: Not yet recruiting
• Trial end date: 2025-01-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165

Criteria

Inclusion Criteria

• Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.

• Deemed by the investigator to be a candidate for phototherapy or systemic therapy.

• ≥ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1

• Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1

Exclusion Criteria:

Target Disease Exceptions:

• Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1

Other protocol-defined inclusion/exclusion criteria apply.